Want to see KVUE full AI Analyst Report?
KVUE Stock Chart & Stats
$19.33
$0.20(1.04%)
At close: 4:00 PM EDT
$19.33
$0.20(1.04%)
Day’s Range― - ―
52-Week Range$14.02 - $20.13
Previous Close$19.48
Volume20.91M
Average Volume (3M)24.03M
Market Cap
$36.24B
Enterprise Value$44.29B
Total Cash (Recent Filing)$1.11B
Total Debt (Recent Filing)$8.48B
Price to Earnings (P/E)21.7
Beta0.02
Next Earnings
Nov 11, 2026EPS Estimate
0.29Next Dividend Ex-DateN/A
Dividend Yield5.52%
Share Statistics
EPS (TTM)0.87
Shares Outstanding1,920,773,400
10 Day Avg. Volume21,778,632
30 Day Avg. Volume24,026,949
Financial Highlights & Ratios
PEG Ratio0.52
Price to Book (P/B)3.06
Price to Sales (P/S)2.18
P/FCF Ratio19.14
Enterprise Value/Market Cap1.22
Enterprise Value/Revenue2.87
Enterprise Value/Gross Profit4.94
Enterprise Value/Ebitda13.99
Forecast
1Y Price Target
$19.25Price Target Upside-0.41% Downside
Rating ConsensusHold
Number of Analyst Covering7
EPS Forecast (FY)1.18
Revenue Forecast (FY)$15.60B
Bulls Say, Bears Say
Bulls Say
Strong ProfitabilityConsistently high gross margins and improved EBIT margin indicate meaningful brand, product-mix, and operating-scale advantages. These supports can help Kenvue fund marketing and innovation while preserving earnings resilience across its consumer health categories.
Diversified PortfolioKenvue’s presence across Self Care, Skin Health and Beauty, and Essential Health reduces reliance on any single product category. Its branded products are distributed through retail, pharmacy, e-commerce, and international channels, supporting durable consumer reach.
Broad-Based Sales GrowthThree consecutive quarters of net and organic sales growth, accompanied by gains across every segment and region, suggest improving commercial execution rather than an isolated category benefit. Continued breadth of growth can strengthen scale and support reinvestment.
Bears Say
Weaker Cash GenerationThe sharp TTM decline in operating and free cash flow reduces the cash available for debt reduction, dividends, innovation, and other strategic investments. Lower cash conversion relative to operating profit also increases the risk of volatility in near-term financial flexibility.
Elevated LeverageDebt of roughly 0.8 times equity is described as manageable, but it leaves Kenvue with less balance-sheet flexibility than lower-levered peers. This can constrain capital allocation and make weaker cash generation more consequential over the next several quarters.
Earnings VolatilityMaterially lower TTM net income despite broadly similar revenue shows that sales are not translating into consistently stronger bottom-line results. Earnings volatility can limit confidence in durable profit conversion and reduce the company’s ability to absorb operating pressures.
Kenvue, Inc. News
KVUE FAQ
What was Kenvue, Inc.’s price range in the past 12 months?
Kenvue, Inc. lowest stock price was $14.02 and its highest was $20.13 in the past 12 months.
What is Kenvue, Inc.’s market cap?
Kenvue, Inc.’s market cap is $36.24B.
When is Kenvue, Inc.’s upcoming earnings report date?
Kenvue, Inc.’s upcoming earnings report date is Nov 11, 2026 which is in 22 days.
How were Kenvue, Inc.’s earnings last quarter?
Kenvue, Inc. released its earnings results on Aug 06, 2026. The company reported $0.31 earnings per share for the quarter, missing the consensus estimate of $0.319 by -$0.009.
Is Kenvue, Inc. overvalued?
According to Wall Street analysts Kenvue, Inc.’s price is currently Overvalued.
Does Kenvue, Inc. pay dividends?
Kenvue, Inc. pays a Monthly dividend of $0.21 which represents an annual dividend yield of 5.52%. See more information on Kenvue, Inc. dividends here
What is Kenvue, Inc.’s EPS estimate?
Kenvue, Inc.’s EPS estimate is 0.29.
How many shares outstanding does Kenvue, Inc. have?
Kenvue, Inc. has 1,920,773,400 shares outstanding.
What happened to Kenvue, Inc.’s price movement after its last earnings report?
Kenvue, Inc. reported an EPS of $0.31 in its last earnings report, missing expectations of $0.319. Following the earnings report the stock price went down -2.492%.
Which hedge fund is a major shareholder of Kenvue, Inc.?
Currently, no hedge funds are holding shares in KVUE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kenvue, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$19.25 (-0.41% Downside)
$19.25 (-0.41% Downside)
Blogger Sentiment
Neutral
KVUE Sentiment 57%
Sector Average 63%
Sector Average 63%
Hedge Fund Trend
Increased
By 10.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.6%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
30.88%
12-Months-Change
Fundamentals
Return on Equity
15.58%
Trailing 12-Months
Asset Growth
-1.46%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Kenvue, Inc.
Kenvue Inc. functions as a global leader in the consumer health sector. The company structures its operations across three primary divisions: Self Care, Skin Health and Beauty, and Essential Health. Within the Self Care unit, it offers a diverse range of products for common conditions like coughs, colds, and allergies, in addition to pain relief, digestive health, and smoking cessation aids, featuring prominent brands such as Tylenol, Nicorette, and Zyrtec. The Skin Health and Beauty segment delivers various solutions for facial, body, hair, and sun protection, recognized under popular labels including Neutrogena, Aveeno, and OGX. Moreover, the Essential Health category provides oral hygiene, infant care, feminine wellness, and wound treatment products, marketed through esteemed brands like Listerine, Johnson's, Band-Aid, and Stayfree. Established in 2022, Kenvue Inc. maintains its corporate headquarters in Skillman, New Jersey, and operates as a subsidiary of Johnson & Johnson.
KVUE Revenue Breakdown
42.17% Self Care
27.20% Skin Health and Beauty
30.63% Essential Health
KVUE Stock 12 Month Forecast
Average Price Target
$19.25
▼(-0.41% Downside)
Technical Analysis
Colgate-Palmolive
―
The Estée Lauder Companies
―
Kimberly Clark
―
Procter & Gamble
―
Unilever
―
Ownership Overview
1.45% Insiders
24.21% Mutual Funds
0.30% Other Institutional Investors
44.30% Public Companies and
Individual Investors